Porcine reproductive and respiratory syndrome virus vaccines: Immunogenicity, efficacy and safety aspects
about
Serum-derived exosomes from non-viremic animals previously exposed to the porcine respiratory and reproductive virus contain antigenic viral proteins.Effects of ribavirin on the replication and genetic stability of porcine reproductive and respiratory syndrome virusRecognition of Highly Diverse Type-1 and -2 Porcine Reproductive and Respiratory Syndrome Viruses (PRRSVs) by T-Lymphocytes Induced in Pigs after Experimental Infection with a Type-2 PRRSV Strain.Augmented immune responses in pigs immunized with an inactivated porcine reproductive and respiratory syndrome virus containing the deglycosylated glycoprotein 5 under field conditionsComparative analysis of routes of immunization of a live porcine reproductive and respiratory syndrome virus (PRRSV) vaccine in a heterologous virus challenge study.Safety and early onset of immunity with a novel European porcine reproductive and respiratory syndrome virus vaccine in young piglets.The Attenuation Phenotype of a Ribavirin-Resistant Porcine Reproductive and Respiratory Syndrome Virus Is Maintained during Sequential Passages in Pigs.Evaluation of the Cross-Protective Efficacy of a Chimeric Porcine Reproductive and Respiratory Syndrome Virus Constructed Based on Two Field Strains.Safety and efficacy of a novel European vaccine for porcine reproductive and respiratory virus in bred gilts.Effect of vaccination with a modified live porcine reproductive and respiratory syndrome virus vaccine on growth performance in fattening pigs under field conditionsMortality Due to Porcine Reproductive and Respiratory Syndrome Virus in Immunocompromised Göttingen Minipigs (Sus scrofa domestica).Virus replicon particles expressing porcine reproductive and respiratory syndrome virus proteins elicit immune priming but do not confer protection from viremia in pigs.A highly pathogenic porcine reproductive and respiratory syndrome virus candidate vaccine based on Japanese encephalitis virus replicon system.Control and eradication of porcine reproductive and respiratory syndrome virus type 2 using a modified-live type 2 vaccine in combination with a load, close, homogenise model: an area elimination study.The Cholera Toxin B Subunit (CTB) Fused to the Porcine Arterivirus Matrix M and GP5 Envelope Proteins Fails to Enhance the GP5-Specific Antibody Response in Pigs Immunized with Adenovectors.Genomic regions associated with host response to porcine reproductive and respiratory syndrome vaccination and co-infection in nursery pigs.Improved Vaccine against PRRSV: Current Progress and Future Perspective.Assessment of listing and categorisation of animal diseases within the framework of the Animal Health Law (Regulation (EU) No 2016/429): porcine reproductive and respiratory syndrome (PRRS)Plant synthetic GP4 and GP5 proteins from porcine reproductive and respiratory syndrome virus elicit immune responses in pigs.Inhibition of proanthocyanidin A2 on porcine reproductive and respiratory syndrome virus replication in vitro.Long duration of immunity against a type 1 heterologous PRRS virus challenge in pigs immunised with a novel PRRS MLV vaccine: a randomised controlled study.Pigs that recover from porcine reproduction and respiratory syndrome virus infection develop cytotoxic CD4+CD8+ and CD4+CD8- T-cells that kill virus infected cellsInitial vaccination and revaccination with Type I PRRS 94881 MLV reduces viral load and infection with porcine reproductive and respiratory syndrome virus
P2860
Q27321003-857E1727-9046-4D7A-8662-BACE4223F5DFQ35131997-4EAF8AB9-2ABE-4029-97A0-A9CCA7C88E34Q36178539-5A92D677-96B4-4731-9748-7C8889AEDC89Q36547978-57EA018D-5D49-46A4-B488-8A00980B601DQ36700988-B0BFFF6A-94A6-4A64-B298-355726D43F28Q36811013-1E3BD524-7EB2-484C-A133-64804C5F69C7Q36811916-568D7AAB-3BCC-4FF4-A086-D9F505855A38Q37203209-FC32BD1A-DCE5-4CEA-9E99-243CCBA184FBQ37315615-62FDC89A-DEF8-4E10-911F-6F088D44AD3EQ37329616-3EA2763D-A36E-4E16-8C0B-E2C112DAA141Q37354948-6BFBB259-6BCF-43B7-BBC0-B18DE400E20EQ38573583-B5ADBD8B-FF26-4054-8DAE-AFEF8A34DB3AQ38663271-D155C2E5-CB73-4570-AEC6-116C52252D3FQ40383874-F001BDEF-C53A-41FE-851D-8D527A9A7DB3Q41392262-67FD71E2-78EA-4BFF-A11E-FA68A3246C32Q44690044-E0403520-2809-4EBC-A306-47CC5F0DF4BAQ47154824-F07F6E9E-B570-46EE-B00F-7056B2CEFE28Q47160201-F949B979-00C7-43AD-A440-81B72BBF998EQ47219938-8B5937C0-4A84-44F9-8A6D-112C2CE9F287Q52681372-85417415-0000-4785-BA85-C86341867EE8Q55383345-52407E53-6D3A-48F5-A5E5-9BCF9A948D1AQ57160272-216FB75F-BF6C-4718-8FB7-CDC96CAF9F17Q58765760-686C3EA9-DC43-4728-86A6-DF541529C51B
P2860
Porcine reproductive and respiratory syndrome virus vaccines: Immunogenicity, efficacy and safety aspects
description
2012 nî lūn-bûn
@nan
2012 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Porcine reproductive and respi ...... y, efficacy and safety aspects
@ast
Porcine reproductive and respi ...... y, efficacy and safety aspects
@en
Porcine reproductive and respi ...... y, efficacy and safety aspects
@nl
type
label
Porcine reproductive and respi ...... y, efficacy and safety aspects
@ast
Porcine reproductive and respi ...... y, efficacy and safety aspects
@en
Porcine reproductive and respi ...... y, efficacy and safety aspects
@nl
prefLabel
Porcine reproductive and respi ...... y, efficacy and safety aspects
@ast
Porcine reproductive and respi ...... y, efficacy and safety aspects
@en
Porcine reproductive and respi ...... y, efficacy and safety aspects
@nl
P2860
P3181
P356
P1476
Porcine reproductive and respi ...... y, efficacy and safety aspects
@en
P2093
Wasin Charerntantanakul
P2860
P3181
P356
10.5501/WJV.V1.I1.23
P407
P577
2012-02-12T00:00:00Z